Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities (2021 - 2025)

Historic Total Liabilities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $1.8 million.

  • InMed Pharmaceuticals' Total Liabilities fell 1445.65% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 1445.65%. This contributed to the annual value of $2.1 million for FY2025, which is 1800.48% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Total Liabilities is $1.8 million, which was down 1445.65% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Total Liabilities peaked at $5.2 million during Q4 2021, and registered a low of $1.3 million during Q3 2023.
  • Its 5-year average for Total Liabilities is $2.7 million, with a median of $2.3 million in 2024.
  • Per our database at Business Quant, InMed Pharmaceuticals' Total Liabilities surged by 6985.2% in 2022 and then plummeted by 6255.3% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Total Liabilities (Quarter) stood at $5.2 million in 2021, then crashed by 50.45% to $2.6 million in 2022, then fell by 3.92% to $2.5 million in 2023, then decreased by 6.57% to $2.3 million in 2024, then fell by 23.69% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.1 million for Q2 2025, and $2.3 million during Q1 2025.